Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Protalix proposes $60 million notes offering

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) is planning to

Read the full 98 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE